Adam Laponis Sells 556 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis sold 556 shares of Twist Bioscience stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $33.16, for a total transaction of $18,436.96. Following the completion of the transaction, the chief financial officer now owns 74,444 shares in the company, valued at approximately $2,468,563.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Twist Bioscience Stock Down 6.1 %

Shares of Twist Bioscience stock opened at $30.68 on Friday. Twist Bioscience Co. has a twelve month low of $11.46 and a twelve month high of $43.21. The company has a fifty day moving average price of $36.29 and a 200 day moving average price of $29.69.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The firm had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. During the same quarter in the previous year, the business posted ($0.74) EPS. The firm’s revenue was up 31.8% compared to the same quarter last year. Equities research analysts expect that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on TWST shares. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and upped their price target for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Barclays decreased their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Scotiabank upped their price target on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 5th.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently added to or reduced their stakes in TWST. Envestnet Asset Management Inc. lifted its holdings in Twist Bioscience by 81.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 5,900 shares of the company’s stock worth $291,000 after buying an additional 2,653 shares in the last quarter. US Bancorp DE raised its stake in shares of Twist Bioscience by 11.8% in the 1st quarter. US Bancorp DE now owns 5,942 shares of the company’s stock valued at $295,000 after purchasing an additional 626 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Twist Bioscience by 81.2% in the 1st quarter. MetLife Investment Management LLC now owns 29,690 shares of the company’s stock valued at $1,466,000 after purchasing an additional 13,308 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Twist Bioscience by 12.1% in the 1st quarter. Rhumbline Advisers now owns 56,408 shares of the company’s stock valued at $2,785,000 after purchasing an additional 6,110 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of Twist Bioscience by 8.3% in the 1st quarter. BlackRock Inc. now owns 4,692,119 shares of the company’s stock valued at $231,696,000 after purchasing an additional 358,217 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.